Clincosm LogoSign in Get a demo

Description of Abdominal and Gluteo-femoral Subcutaneous Adipose Tissue Cell Population in Women - GLUTAB

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Unknown status
CT.gov ID
NCT01605578
Collaborator
(none)
20
Enrollment
1
Location
24
Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to compare, in healthy women, the adipose tissue composition between abdomen and thigh and then determine whether differences exist independently of the state of obesity.

The findings of this study may help to explain the mechanism contributing to a beneficial role of gluteo-femoral fat contrasting with a deleterious role of abdominal fat on cardiovascular and metabolic dysfunctions.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Biopsies
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Description Des Populations Cellulaires Des Tissus Adipeux Sous-cutanés Abdominaux et glutéo-fémoraux Chez la Femme.
Study Start Date :
May 1, 2012
Anticipated Primary Completion Date :
May 1, 2013
Anticipated Study Completion Date :
May 1, 2014

Outcome Measures

Primary Outcome Measures

  1. To compare the number and the phenotype of cells between abdominal and gluteo-femoral adipose tissue in women. [There is no time frame. It's a comparison of adipose tissue composition between two locations, collected both at visit 2 (inclusion).]

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • women between 15 and 45 years old

  • with genital activity

  • stable weight during the previous 3 months

  • BMI from 20 to 28

  • regular menstrual cycles (28 +/- 2 days) during the previous 3 months

  • reliable means of contraception (systemic hormonal contraception, intrauterine contraceptive device, tubal ligation)

  • using the same way of contraception during the previous 3 months

  • normal clinical examination

  • able to be compliant with the schedule of protocol assessments

  • willing and able to provide written informed consent

  • affiliated to a National Health Service

  • agreeing to being registered on the national file for subjects participating in biomedical research

Exclusion Criteria:

  • Exclusions related to significant medical disturbances :

  • type I and II diabetes

  • early menopause

  • serious psychological disorders

  • uncontrolled thyroid disorders

  • know allergy to local anesthetics especially Xylocaine

  • abnormal laboratory results

  • medical history that, in the opinion of the investigator, makes the subject unsuitable for enrollment

  • positive test result for HIV, HCV and/or HBV virus

  • positive pregnancy test

  • Exclusions related to subject lifestyle :

  • smoking > 10 cigarettes per day

  • smoking cessation during the previous 3 months

  • weight fluctuation (>3kg) during the previous 3 months

  • alcohol abuse

  • coffee or tea consumption > 6 cups per day

  • high consumption of drinks comprising xanthine bases (>0.5 liters/day)

  • consumption of drinks (water or herbal teas) > 2 liters per day

  • Exclusions related to previous or concomitant treatments :

  • anticoagulant

  • neuroleptic or antidepressant

  • medication with draining, lipolytic, appetite suppressant and/or slimming effect

  • local or systemic corticosteroid therapy on the test areas

  • hormonal treatment other than contraception

  • diuretic

  • local treatment against cellulitis (mesotherapy,phosphatidylcholine injection, mechanical process)

  • thighs liposuction < 2 years

  • chronic treatment with anti-inflammatory

  • Exclusions related to the subject :

  • unwillingness or inability to comply with the requirements of the protocol

  • previous participation in a clinical trial within 30 days

  • inability to understand and sign the consent due to linguistic or psychic issues

  • subject deprived of liberty or under guardianship, tutorship or judicial protection

  • female who are currently pregnant or breastfeeding or female considering becoming pregnant while in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre d'Investigation Clinique, CHU Purpan Toulouse France 31059

Sponsors and Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Claire Thalamas, Doctor, CHU Purpan (Toulouse)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT01605578
Other Study ID Numbers:
  • C11-48
  • 2011-A01496-35
First Posted:
May 25, 2012
Last Update Posted:
May 25, 2012
Last Verified:
May 1, 2012

Study Results

No Results Posted as of May 25, 2012